<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95346</article-id><article-id pub-id-type="doi">10.7554/eLife.95346</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95346.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Development of a new genotype–phenotype linked antibody screening system</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Watanabe</surname><given-names>Takashi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6184-0375</contrib-id><email>twatanabe@riken.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hata</surname><given-names>Hikaru</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mochizuki</surname><given-names>Yoshiki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Fumie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hasegawa</surname><given-names>Tomoko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Naveen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ohara</surname><given-names>Osamu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3328-9571</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Fukuyama</surname><given-names>Hidehiro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6457-0630</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mb6s476</institution-id><institution>Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mb6s476</institution-id><institution>Laboratory for Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mb6s476</institution-id><institution>Laboratory for Integrated Bioinformatics, RIKEN Center for Integrative Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University</institution></institution-wrap><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04pnjx786</institution-id><institution>Department of Applied Genomics, Kazusa DNA Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Chiba</named-content></addr-line><country>Japan</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/001xjdh50</institution-id><institution>Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>INSERM EST</institution></institution-wrap><addr-line><named-content content-type="city">Strasbourg Cedex</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Srivastava</surname><given-names>Pramod K</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02kzs4y22</institution-id><institution>UConn Health</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>11</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP95346</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-02-20"><day>20</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-08"><day>08</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.06.581777"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-05-03"><day>03</day><month>05</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95346.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-04"><day>04</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95346.2"/></event></pub-history><permissions><copyright-statement>© 2024, Watanabe et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Watanabe et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95346-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95346-figures-v1.pdf"/><abstract><p>Antibodies are powerful tools for the therapy and diagnosis of various diseases. In addition to conventional hybridoma-based screening, recombinant antibody-based screening has become a common choice; however, its application is hampered by two factors: (1) screening starts after Ig gene cloning and recombinant antibody production only, and (2) the antibody is composed of paired chains, heavy and light, commonly expressed by two independent expression vectors. Here, we introduce a method for the rapid screening of recombinant monoclonal antibodies by establishing a Golden Gate-based dual-expression vector and in-vivo expression of membrane-bound antibodies. Using this system, we demonstrate the rapid isolation of influenza cross-reactive antibodies with high affinity from immunized mice within 7 days. This system is particularly useful for isolating therapeutic or diagnostic antibodies, for example during foreseen pandemics.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>membrane-bound Ig expression</kwd><kwd>ngs-based Ig-seq</kwd><kwd>golden gate cloning</kwd><kwd>influenza broadly-reactive</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>26221306</award-id><principal-award-recipient><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><name><surname>Fukuyama</surname><given-names>Hidehiro</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006264</institution-id><institution>RIKEN</institution></institution-wrap></funding-source><award-id>Single cell Project</award-id><principal-award-recipient><name><surname>Watanabe</surname><given-names>Takashi</given-names></name><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><name><surname>Ohara</surname><given-names>Osamu</given-names></name><name><surname>Fukuyama</surname><given-names>Hidehiro</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a crucial advance for pandemic preparedness.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Technical improvements in the rapid isolation of monoclonal antibodies (mAbs) are critical for the diagnostic and therapeutic development of such antibodies. This need became apparent to the general public during the COVID-19 pandemic. Antibodies isolated from convalescent COVID-19 patients are valuable resources for the development of mAb therapeutics and rapid diagnostic tools. Human antibodies can be administered to other patients without the need to humanize in an emergency and with a slight modification of Fc receptor binding (<xref ref-type="bibr" rid="bib3">Balsitis et al., 2010</xref>) to increase the half-life or reduce the risk of antibody-dependent enhancement. Although production costs remain high, the efficiency of generating recombinant antibodies has dramatically improved with the use of mammalian cell lines, and the application of therapeutic antibodies is likely to expand in the near future (<xref ref-type="bibr" rid="bib7">Fang et al., 2017</xref>).</p><p>The gold standard method for isolating mAbs is the hybridoma technology developed by Kohler and Milstein in 1975 (<xref ref-type="bibr" rid="bib14">Köhler and Milstein, 1975</xref>), in which antibody-producing B cells are fused with immortal B cells, called myelomas, to produce long-lasting antibody-producing B cells. In addition to hybridoma technology, new methods have been developed to increase mAb screening efficiency. These include direct immortalization of B cells by gene reprogramming using the Epstein–Barr virus (<xref ref-type="bibr" rid="bib27">Traggiai et al., 2004</xref>) or retrovirus-mediated gene transfer (<xref ref-type="bibr" rid="bib17">Kwakkenbos et al., 2010</xref>), cloning of variable region-encoding genes by single-cell PCR (<xref ref-type="bibr" rid="bib29">Wrammert et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Meijer et al., 2006</xref>), single-cell culture screening (<xref ref-type="bibr" rid="bib16">Kuraoka et al., 2016</xref>), and in vitro screening of recombinant antibody libraries (<xref ref-type="bibr" rid="bib4">Clackson et al., 1991</xref>; <xref ref-type="bibr" rid="bib8">Feldhaus et al., 2003</xref>; <xref ref-type="bibr" rid="bib10">Harvey et al., 2004</xref>; <xref ref-type="bibr" rid="bib24">Schaffitzel et al., 1999</xref>; <xref ref-type="bibr" rid="bib19">Mazor et al., 2007</xref>). Some of these methods have successfully yielded high-affinity antibodies in various formats, including single variable domain on a heavy chain or single-chain fragment variable antibodies. Although hybridoma technology is highly reliable for the isolation of valuable antibodies from animal models, such as mice, rats, and hamsters, it is time-consuming and requires technical skill. The development of a new fusion partner cell line, SPYMEG, has enabled the production of human hybridomas and opened a new direction for the isolation of human mAbs (<xref ref-type="bibr" rid="bib15">Kubota-Koketsu et al., 2009</xref>). Although many of these new technologies have increased the throughput for mAb isolation, the procedure still requires significant resources and time.</p><p>To dramatically enhance the efficiency of mAb isolation, we used next-generation sequencing (NGS) technology, which has revolutionized the sequencing of immunoglobulin (Ig) variable-region genes. For instance, tens of thousands of Ig genes specific to certain antigens can be identified by combining droplet-based single-cell isolation with DNA barcode antigen technology, followed by NGS (<xref ref-type="bibr" rid="bib25">Setliff et al., 2019</xref>). Although Ig genes can be sequenced at high throughput, there is no method for screening antibodies in a high-throughput format that is compatible with NGS technology.</p><p>In this study, we developed a new functional screening method that is compatible with NGS to rapidly identify antigen-specific clones. We first generated an Ig dual-expression vector using Golden Gate Cloning (<xref ref-type="bibr" rid="bib13">Kirchmaier et al., 2013</xref>), which enabled the linkage of heavy-chain variable and light-chain variable DNA fragments obtained from a single-sorted B cell, followed by the expression of membrane-bound Ig. This single-step procedure enabled the enrichment of antigen-specific, high-affinity Igs by flow cytometry, which is significantly faster than conventional cloning-based methods that require sequential steps. To demonstrate the efficiency of our new method, we screened for potent broadly reactive antibodies (<xref ref-type="bibr" rid="bib22">Okuno et al., 1993</xref>; <xref ref-type="bibr" rid="bib6">Ekiert et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Impagliazzo et al., 2015</xref>) against the influenza virus in an experimental mouse model using our technology. Broad reactivity antibodies allow for the development of influenza vaccines that are effective across seasonal variations in influenza strains, which can only be accomplished by screening a large number of candidate antibodies. We first raised cross-reactive B cells against various hemagglutinin (HA) antigens from the influenza virus by sequential immunization with heterotypic HA antigens from group 1 influenza. Using this technology, we obtained several mAbs that bind to other group 1 HA antigens, and even to group 2 HA antigens, of the influenza virus. Our technology can also be applied to human antibody screening and represents a new line of mAb screening that accelerates the isolation of therapeutic and diagnostic mAbs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Rapid membrane-bound dual Ig expression screening system</title><p>Cloning-based Ig screening involves several steps: cloning two Ig gene fragments that encode heavy and light chains independently from a single cell, co-expressing these Ig chains, and purifying individual recombinant antibodies. These steps are labor intensive. We established a new antibody screening system for the isolation of valuable mAbs (details in the methods). Eventually, the antigen-binding Ig transformants were collected by sorting in a bulk fashion, and the unique CDR3 region and clones of interest were identified using the Ig-seq database (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>System to link the antigen-binding feature with the Ig repertoire genetic information.</title><p>(<bold>A</bold>) Single cell-sorted B cells were subjected to two processes: Ig-seq database building and Ig-expressing transformant library preparation. Antigen-binding Ig transformants were collected by sorting in bulk and the sequences of the unique CDR3 regions and clones of interest were identified by referring to the Ig-seq database. The duration of each steps are indicated. (<bold>B</bold>) To express both Ig heavy and kappa/lambda chains in a single-expression vector, we generated a dual-expression vector. Four gene fragments were assembled by the Golden Gate method using the BsaI restriction enzyme. They included: (1) the destination vector containing the Ig kappa constant gene and the ccdB Chloramphenicol cassette for negative selection, (2) fragments containing the Ig heavy constant gene fused to <italic>Venus</italic> derived from the donor vector, (3) the Ig heavy variable gene fragment, and (4) the Ig light variable gene fragment. (<bold>C</bold>) Individually purified plasmids were transiently transfected to the floating human FreeStyle 293 cell line. Igs were expressed on the cell surface in 2 days, and expression levels were confirmed and normalized by <italic>Venus</italic> expression, since the Ig heavy chain was fused to <italic>Venus</italic> at the cytoplasmic domain tail.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The Ig repertoires are visualized using the in-house software.</title><p>Overview of heavy (V–D–J) and light (V–J) chain usages (<bold>A</bold>), and the repertoire clonality (<bold>B</bold>) is shown. (<bold>C</bold>) The mutation rates and their positions of heavy chains in three cell populations (PR8+, H2+, PR8 +H2+) are compared. (<bold>D</bold>) The lengths of CDR3 of heavy chains of three cell populations (PR8+, H2+, PR8 +H2+) are compared.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Progression flowchart.</title><p>The process for efficiently isolating influenza cross-reactive antibodies from mouse germinal center B cells with high affinity is shown. Experiment outcome flow numbers of clones in each step are indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Sorting strategy.</title><p>CD43 MACS B cells from the spleen purified using negatively charged beads were sorted for IgG1 + cells and then separated into H2 and PR8. The majority of cross-reactive IgG1 + cells (red box) were CD38 + cells, most likely in the memory compartment. For reference, the CD38 staining pattern of total live B cells is shown at the bottom right.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig1-figsupp3-v1.tif"/></fig></fig-group><p>We generated a dual-expression vector to express both Ig heavy and kappa/lambda in a single-expression vector (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These plasmids were individually transfected transiently to the floating human FreeStyle 293 cell line. Igs were expressed on the cell surface within 2 days, and their expression could be confirmed and normalized by <italic>Venus</italic> (<xref ref-type="bibr" rid="bib21">Nagai et al., 2002</xref>) expression since the Ig heavy chain is fused with <italic>Venus</italic> at the cytoplasmic domain tail (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The advantage of this system is the rapid enrichment of clones of interest through bulk screening. In the current single-cell-based cloning/screening, plasmid DNA extracted from the collected antigen-binding bulk transformants is sequenced for the heavy chain CDR3 region. The CDR3 region is unique and can be used for the identification of a clone (<xref ref-type="bibr" rid="bib5">D’Angelo et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Xu and Davis, 2000</xref>). This membrane-bound Ig expression system links antigen-binding features and genetic information of the Ig repertoire.</p></sec><sec id="s2-2"><title>Building the Ig-seq database and analysis</title><p>As a model experiment, we obtained broadly reactive antibodies against influenza viruses using multiple HA probes. We prepared two HA proteins as probes: A/Puerto Rico/8/1934 (H1N1), designated as PR8, and A/Okuda/1957 (H2N2), designated as H2. A total of 374 IgG1<sup>+</sup> B cells of either PR8<sup>+</sup> (204 cells), H2<sup>+</sup> (99 cells), or PR8<sup>+</sup>H2<sup>+</sup> (71 cells) were collected in a single-cell fashion. We obtained sequences of 284 independent clones. The success rate of cloning the paired Ig fragments was 75.9%. An overview of heavy chain V-D-J and light chain V-J usage and repertoire clonality is shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>. Mutation rates and CDR3 lengths of the heavy chains of the three cell populations (PR8<sup>+</sup>, H2<sup>+</sup>, and PR8<sup>+</sup>H2<sup>+</sup>) were comparable (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and D</xref>). These results indicate that broadly reactive antibodies do not require unique genetic traces to obtain breadth in our experimental setup.</p></sec><sec id="s2-3"><title>Isolation of H2- and H1-reactive B cells</title><p>On day 2 after transfection of individual 284 clones, the transformants were mixed and stained with HA probes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). As shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>, we selected three prominent populations, H1<sup>+</sup>H2<sup>+</sup> (cross), H2<sup>+</sup> (H2), and H1<sup>+</sup> (H1), and collected them in bulk. In contrast to bacterial transfection, mammalian cell lines, such as FreeStyle 293 cells, can contain multiple plasmids in a cell and ectopically express multiple proteins. Therefore, we decided to mix the transformants instead of plasmids. We sorted a total of 2981 cells, classified into three strong binder populations, and performed sequencing (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). These bulk Ig-seq data are referred to as Ig-seq data, as described above. A total of 190 clones from the three populations were verified for their sequences and HA binding by flow cytometry analysis, as shown in <xref ref-type="fig" rid="fig2">Figure 2C</xref>; 110 ‘H1<sup>+</sup>’, 67 ‘H2<sup>+</sup>’, and 13 ‘cross’ clones were successfully isolated. In parallel, all the transformants were examined individually for comparison with the bulk method. One hundred thirty-eight transformants were verified for their binding to HAs by flow cytometry. Of these, 81 ‘H1<sup>+</sup>’, 48 ‘H2<sup>+</sup>’, and ９ ‘cross’ clones were successfully isolated (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Eight of the 13 ‘cross’ clones obtained in the bulk examination overlapped with ‘cross’ clones obtained in the individual examination (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>); the binding of one cross clone (D11p4) from the individual examination was so weak that it was not included in the gates sorted in bulk (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Comparison of the bulk and the individual examinations demonstrated that the rapid bulk method is sufficient for selecting clones of interest.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Isolation of H2 and H1-reactive B cells.</title><p>(<bold>A</bold>) Mixture of Ig-expressing transformant libraries stained with HA probes. (<bold>B</bold>) Three strong HA-binding populations, H1<sup>+</sup>H2<sup>+</sup> (cross), H2<sup>+</sup> (H2), and H1<sup>+</sup> (H1), were sorted and collected in a bulk fashion. Then, these three collected populations were and sequenced. (<bold>C</bold>) The bulk Ig-seq data were referred to as the single-cell Ig-seq data. Heatmap indicates the appearance rate of individual clone in each box shown in B (H1, H2, or Cross) among sorted 2981 cells of mixture of 190 clone transformants. H1<sup>+</sup>H2<sup>+</sup> (cross) clones are shown on the right columns. High to low appearance rate reflects red to blue color. (<bold>D</bold>) The individual flow cytometry profile of 13 ‘Cross’ transformants obtained by the bulk examination are shown and red labeled ones are also found by the individual examination(red). (<bold>E</bold>) A summary of the results in comparison of the bulk and individual examination methods.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>SPR profiles of kinetics analysis of nine clones, A6p4, B10p2, C10p2, A2p1, D11p4, E11p2, G6p2, D4p4, and G12p4 using a BIAcore 3000 machine (GE Healthcare).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Two hundred and eighty-four clones are plotted in a two-dimensional map of phylogeny trees for heavy and light chain genes.</title><p>Nine mAb clones are overlaid in green. Six ‘cross’ clones are located in a major cluster. B10p2 and C10p2 are co-localized and distant from the cluster. A6p4 is uniquely located in the map.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>The affinity of antigen-antibody binding (in this case, probe and membrane-bound antibody expressing cell) can be inferred from the population shift (flow cytometry analysis).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig2-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Characterization of ‘cross’ clones for broad reactivity against the influenza virus</title><p>We decided to further characterize eight common clones between the individual and bulk examinations and one short-ranged clone, D11p4. By generating a secretory form of mAbs for these nine ‘cross’ clones from the individual examination, we characterized their affinity and broadness using six different HA antigens from strains A/Okuda/1957 (H2N2) named for H2, A/Puerto Rico/8/1934 (H1N1) for PR8, A/California/2009 (X-179A) [H1N1] Pdm09 for Cal, A/Texas/50/2012 (X-223) [H3N2] for H3, A/Egypt/N03072/2010(H5N1) for H5, and A/Brisbane/59/2007 [H1N1] (<xref ref-type="bibr" rid="bib11">Impagliazzo et al., 2015</xref>) for Stem. We determined the affinities (K<sub>d</sub>) of the antibodies for the six HA antigens using surface plasmon resonance analysis (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), which ranged from 500 to 100 nM. With the highest affinity among them, the C10p2 antibody bound to Cal at K<sub>d</sub> ≃ 5.66×10<sup>−10</sup> (M). Surprisingly, the antibodies showed a broader spectrum of HA binding among the influenza strains. Seven of the nine mAbs bound to HA from the highly pathogenic avian influenza strain H5N1. Furthermore, six antibodies that bound to H3 were categorized into group 2 (<xref ref-type="bibr" rid="bib9">Gamblin and Skehel, 2010</xref>). In addition, we observed that two of the broadly reactive antibodies recognized the stem region of the HA of A/Brisbane/59/2007. A possible scenario for other stem-negative antibodies is that they may either bind to the stem region of other strains or to the head region of HA. We tested whether some of these antibodies shared features with classic broadly neutralizing antibodies. C179, the first broadly neutralizing mouse antibody isolated in 1993 (<xref ref-type="bibr" rid="bib22">Okuno et al., 1993</xref>), reacts with the stem region of HAs from group 1 influenza virus strains (<xref ref-type="bibr" rid="bib9">Gamblin and Skehel, 2010</xref>). C179 binds to HAs from group 1 influenza viruses, including H1N1, H2N2, and H5N1. A competition assay for the binding of H2 and PR8 revealed that A6p4 competes with C179 (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In addition, our two-dimensional phylogeny map indicated that A6p4 was unique to all clones (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Note that we used NSP2 as a negative control antibody, which binds specifically to the HA from A/California/2009 (X-179A) [H1N1] Pdm09 (<xref ref-type="bibr" rid="bib1">Adachi et al., 2015</xref>). These results demonstrate that we were able to isolate a broadly reactive mAb with an affinity comparable to that of a classic broadly reactive mAb (C179) using our technology.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Competition assay of ‘cross’ Ig-transformants using C179, a broadly-reactive mAb binding to the Stem region of HA, and NSP2 (Narita strain-specific mAb), a strain-specific mAb that binds to the head region of HA.</title><p>On the right panel, two stem-reactive clones (see <xref ref-type="table" rid="table1">Table 1</xref>) were examined reciprocally with combination of transformant and recombinant antibodies.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95346-fig3-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Affinities (K<sub>d</sub>) of the antibodies to six HA antigens from strains A/Okuda/1957(H2N2), termed H2, A/Puerto Rico/8/1934(H1N1), termed PR8, A/California/2009 (X-179A) [H1N1] Pdm09, termed Cal, A/Texas/50/2012 (X-223) [H3N2], termed H3, A/Egypt/N03072/2010(H5N1), termed H5, and A/Brisbane/59/2007 (H1N1), termed Stem, were determined using surface plasmon resonance analysis.</title><p>H2, PR8, Cal, and H5 belong to group 1, and H3 belongs to group 2. High (red), Middle (orange), and Low (blue).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Group</th><th align="left" valign="top">1</th><th align="left" valign="top">1</th><th align="left" valign="top">1</th><th align="left" valign="top">2</th><th align="left" valign="top">1</th><th align="left" valign="top">1</th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>H2</bold></td><td align="left" valign="top"><bold>PR8</bold></td><td align="left" valign="top"><bold>Cal</bold></td><td align="left" valign="top"><bold>H3</bold></td><td align="left" valign="top"><bold>H5</bold></td><td align="left" valign="top"><bold>Stem</bold></td></tr><tr><td align="left" valign="top"><bold>A6p4</bold></td><td style="background-color: #E57373;">4.51E-08</td><td style="background-color: #FFB74D;">1.41E-06</td><td style="background-color: #FFB74D;">1.14E-05</td><td style="background-color: #90CAF9;"/><td style="background-color: #FFB74D;">2.91E-05</td><td style="background-color: #E57373;">1.59E-08</td></tr><tr><td align="left" valign="top"><bold>B10p2</bold></td><td style="background-color: #E57373;">6.75E-09</td><td style="background-color: #E57373;">2.3E-09</td><td style="background-color: #E57373;">3.29E-09</td><td style="background-color: #90CAF9;"/><td style="background-color: #90CAF9;"/><td style="background-color: #90CAF9;"/></tr><tr><td align="left" valign="top"><bold>C10p2</bold></td><td style="background-color: #E57373;">1.66E-09</td><td style="background-color: #E57373;">1.29E-09</td><td style="background-color: #E57373;">5.66E-10</td><td style="background-color: #90CAF9;"/><td style="background-color: #90CAF9;"/><td style="background-color: #E57373;">4.26E-08</td></tr><tr><td align="left" valign="top"><bold>A2p1</bold></td><td style="background-color: #FFB74D;">2.49E-06</td><td style="background-color: #FFB74D;">1.42E-07</td><td style="background-color: #FFB74D;">1.14E-05</td><td style="background-color: #FFB74D;">1.25E-04</td><td style="background-color: #FFB74D;">1.91E-05</td><td style="background-color: #90CAF9;"/></tr><tr><td align="left" valign="top"><bold>D11p4</bold></td><td style="background-color: #FFB74D;">7.93E-07</td><td style="background-color: #FFB74D;">1.72E-06</td><td style="background-color: #FFB74D;">1.04E-06</td><td style="background-color: #FFB74D;">1.36E-05</td><td style="background-color: #FFB74D;">1.05E-11<xref ref-type="table-fn" rid="table1fn2">*</xref></td><td style="background-color: #90CAF9;"/></tr><tr><td align="left" valign="top"><bold>E11p2</bold></td><td style="background-color: #E57373;">4.4E-08</td><td style="background-color: #E57373;">1.86E-08</td><td style="background-color: #FFB74D;">1.67E-06</td><td style="background-color: #FFB74D;">2.92E-07</td><td style="background-color: #FFB74D;">2.37E-07</td><td style="background-color: #90CAF9;"/></tr><tr><td align="left" valign="top"><bold>G6p2</bold></td><td style="background-color: #E57373;">3.51E-08</td><td style="background-color: #E57373;">3.53E-08</td><td style="background-color: #E57373;">1.44E-08</td><td style="background-color: #FFB74D;">1.78E-05</td><td style="background-color: #E57373;">3.05E-08</td><td style="background-color: #90CAF9;"/></tr><tr><td align="left" valign="top"><bold>D4p4</bold></td><td style="background-color: #FFB74D;">1.1E-05</td><td style="background-color: #FFB74D;">1.78E-05</td><td style="background-color: #FFB74D;">6.4E-05</td><td style="background-color: #FFB74D;">4.38E-05</td><td style="background-color: #FFB74D;">2.47E-05</td><td style="background-color: #90CAF9;"/></tr><tr><td align="left" valign="top"><bold>G12p4</bold></td><td style="background-color: #FFB74D;">1.45E-07</td><td style="background-color: #FFB74D;">1.52E-07</td><td style="background-color: #FFB74D;">5.7E-07</td><td style="background-color: #FFB74D;">9.44E-07</td><td style="background-color: #FFB74D;">1.58E-07</td><td style="background-color: #90CAF9;"/></tr></tbody></table><table-wrap-foot><fn><p>Surface plasmon resonance (Biacore) KD (M).</p></fn><fn id="table1fn2"><label>*</label><p>The affinity of D11p4 for H5 was low and inaccurate (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The discovery of therapeutic antibodies as well as their demand are increasing (<xref ref-type="bibr" rid="bib12">Kaplon et al., 2023</xref>). Efficiently isolating one biologically significant antibody from the 10<sup>13</sup> antibody repertoire is challenging. The hybridoma method has long been used for this purpose and remains reliable. However, the fusion rate of B and myeloma cells is &lt;0.001% in this method; therefore, the number of hybridomas obtained from one individual B cell is limited to several hundred clones, limiting its use in the production of mAbs. As an alternative choice, cloning-based antibody screening has gained popularity, especially for human antibody discovery, because of the lack of a human myeloma cell line similar to that used for murine cell fusion partners. The SPYMEG cell line can generate antigen-specific antibody-producing cells by fusing the murine SP2/0 myeloma cell line and human megakaryoblastic leukemia cell line MEG-01 with human PBMCs (<xref ref-type="bibr" rid="bib15">Kubota-Koketsu et al., 2009</xref>; <xref ref-type="bibr" rid="bib26">Soni et al., 2018</xref>). In our study, we sorted IgG１＋ B cells. Most of those cross-reactive B cells were memory B cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). As shown in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, the cloning efficiency exceeded 75%. Our functional screening by selecting strong binders allowed us to narrow down the number of clones to 13 cross-reactive B cells. One of the clones had a strong affinity of K<sub>d</sub> ≃ 5.66×10<sup>−10</sup> (M). Notably, the generation of antibodies that target regions other than HA cannot be ruled out since the immunization antigen and the detected antigen were the same. However, as shown in <xref ref-type="table" rid="table1">Table 1</xref>, the cross-reactive antibodies obtained in this study exhibited characteristic binding abilities to each of the six types of HAs. If these were antibodies recognizing His-tag, they would bind to all six types of HA, indicating that these cross-reactive antibodies were no His-specific clones.</p><p>In addition to gene expression profiling, NGS facilitates antibody repertoire analysis. However, despite breakthroughs in sequencing technology, the process of linking antibody function and its genes is still long and labor intensive. To overcome this issue, we developed a new antibody screening system to directly link antigen–antibody binding (as a function) with a gene encoding the antibody by expressing its membrane-bound form. Among conventional cloning-based mAb isolation methods, this system demonstrates several advantages. (1) Membrane Ig expression can link the antigen-binding feature of membrane-expressed Ig, which can be linked to Ig DNA sequence information using our plasmid construct. Similar to the panning procedure used in phage display (<xref ref-type="bibr" rid="bib23">Petropoulos, 2012</xref>), antigen-binding cells carry the plasmid encoding Ig genes through surface Ig so that the selection process in bulk format enriches the relevant plasmids for use in further experiments. (2) The dual Ig expression vector links heavy- and light-chain genes, which reduces the plasmid preparation time and stock by half. (3) Highly reliable Golden Gate Cloning technology using type IIs restriction enzymes can readily generate plasmid clones. This reduced the time required to generate an Ig plasmid library. (4) The population profile, defined by the fluorescence intensity during flow cytometry, directly reflected the affinity of a clone (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Lima et al. developed a dual Ig expression vector, similar to the one we report here, to produce secretary antibodies and succeeded in obtaining functional monoclonal antibodies from SARS-CoV-2 infected individuals (<xref ref-type="bibr" rid="bib18">Lima et al., 2022</xref>). Collectively, our technology streamlines the isolation of mAbs for therapy and diagnosis.</p><sec id="s3-1"><title>Conclusion</title><p>Our findings indicate that the developed antibody presentation system facilitates antibody functional analysis and is well suited for the discovery of antibodies important for infectious diseases when combined with conventional NGS-based antibody repertoire analysis. Compared with droplet-based experimental systems, well-based systems are limited in the number of cells they can process. Furthermore, experiments involving infectious bacteria and viruses have imposed limitations on human experimentation. To solve these problems, the automation of experiments will become important in the future. By combining our screening system with robotic automation of experiments, it will be possible to obtain useful mAbs for various diseases quickly and in large quantities, which has broad implications for the development of vaccines against various diseases.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Aequorea coerulescens</italic>)</td><td align="left" valign="bottom">venus</td><td align="left" valign="bottom">RIKEN BRC; <xref ref-type="bibr" rid="bib21">Nagai et al., 2002</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">DH5α</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">EC0112</td><td align="left" valign="bottom">competent cells</td></tr><tr><td align="left" valign="bottom">Genetic reagent (F’ Episome)</td><td align="left" valign="bottom">ccdB</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">V79020</td><td align="left" valign="bottom">pcDNA3.1 (+) Mammalian Expression Vector</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">FreeStyle 293</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">R79007</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Antibody expression vector</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Plasmid construct to transfect and express the antibody.</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Mouse splenocytes</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">CLEA Japan, Inc.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD43 MicroBeads (Mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec, Inc.</td><td align="char" char="hyphen" valign="bottom">130-049-801</td><td align="left" valign="bottom">Add 10 μL of Anti-CD43 (Ly-48) MicroBeads (mouse) per 10⁷ total cells (1:1000 dilution)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-mIgG1 (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">To obtain a large amount of secretory antibodies</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.4-kappa (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">To obtain a large amount of secretory antibodies</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">BsaI_IL6sp_L</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTAGGGTCTCAAGCAGATGAACTCCTTCTCCACAAGCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mC_G_new2_BsaI</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTAGGTCTCCCACACACAGGGGCCAGTGGATAGAC</named-content></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Anti-HA antibodies</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Nine cross reactive antibodies</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BsaI-HFv2</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">NEB #R3733</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">T4 DNA ligase</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">M0202T</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AddaVax</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">vac-adx-10</td><td align="left" valign="bottom">adjuvant</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BONSCI</td><td align="left" valign="bottom">in-house software</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Ig database construction and visualization of the Ig repertoire</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">CM5 sensor chip</td><td align="left" valign="bottom">GE Healthcare Technologies</td><td align="left" valign="bottom">BR100530</td><td align="left" valign="bottom">3 sensor chips</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Protein purification of influenza HAs (H1 and H2) as antigens</title><p>A mixture of 25.7 µg of HA, comprising H1 strain A/Puerto Rico/8/1934 (PR8), H1 strain A/California/7/2009 (X-179A), H2 strain A/Okuda/1957 (H2), H3 strain A/Texas/50/2012 (X-223), or H5 strain A/Egypt/[N03072/2010], 1.3 µg of NA (Strain-matched), and 3 µg of BirA-expressing plasmids were transfected into Expi293 cells using the Expifectamine 293 transfection kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The cells were then cultured in Expi293 Expression Medium (Thermo Fisher Scientific) supplemented with D-biotin at a final concentration of 100 µM for in vivo BirA biotinylation in a humidified incubator containing 8% CO<sub>2</sub> at 37 °C and 125 rpm. If biotinylation was not necessary, transfection was performed without BirA, and cell culture was carried out without D-biotin. Culture supernatants were harvested 3 days post-transfection and filtered through a 0.45 μm filter (Merck Millipore, Burlington, MA, USA). All proteins were purified with a Talon metal affinity resin (Takara Bio USA, Mountain View, CA, USA) and dialyzed against pyrogen-free PBS. The oligomeric state and purity were determined at 25 °C by size-exclusion chromatography on a Superdex 200 10/300 GL column (GE Healthcare Technologies, Chicago, IL).</p></sec><sec id="s4-2"><title>HA (H1 and H2) protein immunization</title><p>Two BALB/c mice were intraperitoneally immunized sequentially, 2 weeks apart, with 15 µg of H1 (PR8) HA, followed by 15 µg of H2 HA protein as an antigen and supplemented with AddaVax adjuvant (InvivoGen, San Diego, CA, USA). Two weeks after the second immunization, the mice were sacrificed, and their splenocytes were used for the experiment. BALB/c mice were purchased from CLEA Japan (CLEA Japan, Inc, Tokyo, Japan). All animal experiments were performed using protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the RIKEN Yokohama Branch (Project title: Immunological memory and vaccine development/Approval No.: 2019–001).</p></sec><sec id="s4-3"><title>Fluorescence-activated cell sorting</title><p>Using ACK (Ammonium-Chloride-Potassium) lysing buffer-treated splenocytes, CD43-negative B cells were collected using AutoMACS (Miltenyi Biotec, Inc, Bergisch Gladbach, North Rhine-Westphalia, Germany) and stained with IgG1 (Bv510), non-biotinylated His-tagged purified recombinant His-tagged H1 (PR8) protein, and CD38 (PE-Cy7) on ice for 30 min. After washing three times, the cell suspension was incubated with Alexa Fluor 488-labeled anti-His antibodies on ice for 30 min. After washing three times, biotinylated purified recombinant H2 protein was incubated on ice for 30 min. Furthermore after washing three times, the cell suspension was incubated with Brilliant Violet 421-conjugated streptavidin on ice for 3 min. We used 7-AAD for excluding dead cells. Next, the B cells were subjected to single-cell sorting using a BD FACSAria III (BD Biosciences, Franklin Lakes, NJ, USA) and collected into 96-well plates pre-loaded with lysis buffer. The single cells in the lysis buffer were immediately snap-frozen on powdered dry ice and stored at −80 °C.</p></sec><sec id="s4-4"><title>Amplification of a paired B-cell repertoire amplicon from a single cell</title><p>Single cells were dropped into pre-loaded plates containing 4 µL/well of lysis buffer (2 U/µL RNase inhibitor, 0.5×PBS, 10 mM DTT) and 1 µL of 10 µM Oligo(dT)18 Primer. Cell lysates were incubated at 70 °C for 90 s, followed by incubation at 35 °C for 15 s, and then placed on ice for 2 min. For first-strand cDNA synthesis, 5 µL of RT mix (2×PCR buffer, 5 mM DTT, 2 mM dNTP Mix, 10 U RNase inhibitor, 100 U SuperScript III Reverse Transcriptase) was added to the cell lysate and incubated consecutively at 35 °C for 5 min, 45 °C for 20 min, 70 °C for 10 min, and 4 °C for chilling. For primer digestion, 5 µL of the primer digestion mix (1×ExoI Buffer, 7.5 U Exonuclease I) was prepared and incubated at 37 °C for 30 min, 80 °C for 20 min, and 4 °C for chilling. For the poly-A tailing reaction, 5 µL of the poly-A tailing reaction mix (4×PCR buffer, 5 mM dATP, 0.1 U RNase H, 60 U Terminal transferase) was prepared and incubated at 37 °C for 50 s, 65 °C for 10 min, and 4 °C for chilling. For the 2nd strand cDNA synthesis, 25 µL of the amplification mix (1×KAPA HiFi HotStart ReadyMix, 400 nM SMART_dT primer, 10 µL of poly-A tailing product, 1.5 µL of nuclease-free H<sub>2</sub>O) was prepared and incubated at 95 °C for 3 min, 40 °C for 1 min, 65 °C for 10 min, and 72 °C for 5 min and chilled. For the cDNA amplification using an Ig-specific outer primer set, 20 µL of the outer amplification mix (1×KOD FX Neo buffer, 400 µM dNTPs, 1×UPM, 300 nM outer primer, 3.5 µL of the SMART product, 0.5 U KOD FX Neo polymerase) was prepared and incubated at 94 °C for 2 min, followed by 25 cycles at 98 °C for 10 s, 60 °C for 30 s, and 68 °C for 45 s, and then chilled. For cDNA amplification with an Ig-specific inner primer set, 20 µL of the inner amplification mix (1×KOD FX Neo buffer, 400 µM dNTPs, 500 nM 5’ matrix primer mix, 500 nM 3’ matrix primer mix, 3.5 µL of the outer cDNA amplified product, 0.5 U KOD FX Neo polymerase) was prepared and incubated at 94 °C for 2 min, followed by 25 cycles at 98 °C for 10 s, 60 °C for 30 s, and 68 °C for 45 s and then chilled. Finally, 3 µL of the amplified inner cDNA product was used for further plate indexing by amplification. Then, 20 µL of the plate-indexing amplification mix (1×KOD FX Neo buffer, 400 µM dNTPs; 500 nM i5-Fwd or i7-Fwd, 500 nM i7-Rev or i5-Rev; 2 µL of the inner cDNA amplified product; 0.5 U KOD FX Neo polymerase) was prepared and incubated at 94 °C for 2 min, followed by 25 cycles at 98 °C for 10 s, 60 °C for 30 s, and 68 °C for 45 s, and then chilled. All primers used are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a and b</xref>.</p></sec><sec id="s4-5"><title>Paired-end Illumina sequencing strategy and analysis</title><p>The libraries were sequenced on a MiSeq instrument (Illumina, San Diego, CA, USA) following the manufacturer’s protocol. As the sequencing length was limited to 2×300 bp, we used the following strategy. Amplicons in both orientations were generated using an Illumina adapter sequence. Then, asymmetric 400+100 nt paired-end sequencing was performed to obtain high-quality 400+400 nt paired-end sequences of the original cDNA molecule. This approach provided a sufficient sequencing length to capture extra-long Ig variants. We followed the method by <xref ref-type="bibr" rid="bib28">Turchaninova et al., 2016</xref>. Only reads that met the following four conditions were used as the resulting Ig sequences: (1) reads with a length of 260 nt or more; (2) cumulative clustered reads representing the top 5% of the entire reads; (3) 5'- and 3'-reads overlapping a length of 20 bases or more; and (4) a total length of 460±50 bp for heavy chain or 390±40 bp for light chain. All resulting sequence data were analyzed using IMGT/High V-QUEST (<ext-link ext-link-type="uri" xlink:href="http://www.imgt.org/IMGT_vquest/vquest">http://www.imgt.org/IMGT_vquest/vquest</ext-link>) for annotation (<xref ref-type="bibr" rid="bib2">Alamyar et al., 2012</xref>). Using the sequences and annotations, Ig database construction and visualization of the Ig repertoire were performed using the in-house BONSCI software.</p></sec><sec id="s4-6"><title>Construction of a mouse IgG/IgK expression plasmid</title><p>The BsaI restriction sites were inserted into the paired B-cell repertoire amplicon from a single cell using PCR. The destination vector contained the IL6 signal peptide, EF1a promoter, ccdB gene, and mouse IgK Fc region. The donor vector contained the mouse IgG1 Fc region, the <italic>Venus</italic> gene, and the EF1a promoter. The paired B-cell repertoire amplicons, destination vector, and donor vector containing BsaI restriction sites were assembled using our assembly method. For this step, 10 μL of the assembly mix (1×T4 DNA ligase buffer, 1×BSA, 1 U BsaI restriction enzyme, 40 U T4 DNA ligase, 100 ng heavy chain amplicon, 100 ng light chain amplicon, 100 ng destination vector, and 100 ng donor vector) was prepared and incubated for 25 cycles at 37 °C for 3 min, 16 °C for 4 min, 50 °C for 5 min, and 80 °C for 5 min, and then chilled. The antibody sequence that entered the construct was fused to the <italic>Venus</italic> sequence and expressed in membrane form.</p></sec><sec id="s4-7"><title>Antibody display on FreeStyle 293 cultured cells</title><p>One microgram of antibody-expressing plasmid was transfected into 1x10<sup>6</sup> FreeStyle 293 cells in 1 mL culture using the 293fectin Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions and cultured in FreeStyle 293 Expression Medium (Thermo Fisher Scientific) in a humidified incubator with 8% CO<sub>2</sub> at 37 °C and 125 rpm. Antibodies were displayed on the surface of cultured cells, which enabled the determination of antigen specificity. Furthermore, the antibody-display cells were tested for binding activity with Alexa647-labeled H1 and Alexa568-labeled H2 (Alexa Fluor Antibody Labeling Kits, ThermoFisher Scientific) using a BD FACSAria III (BD Biosciences).</p></sec><sec id="s4-8"><title>Antibody production</title><p>To obtain a large amount of secretory antibodies, PCR fragments from the antibody-expressing plasmid were cloned into the pcDNA3.4-mIgG1 or pcDNA3.4-kappa vectors. A mixture of 15 μg of pcDNA3.4-V-gene-mIgG1 vector and 15 μg of pcDNA3.4-V-gene-kappa vector was transfected into Expi293 cells using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific), according to the manufacturer’s instructions, and cultured in Expi293 Expression Medium (Thermo Fisher Scientific) in a humidified 8% CO<sub>2</sub> incubator at 37 °C and 125 rpm. Then, 5 days post-transfection, the culture supernatants were harvested, and all proteins were purified with PureSpeed IMAC resin (Mettler Toledo, Columbus, OH, USA), according to the manufacturer’s instructions.</p></sec><sec id="s4-9"><title>Surface plasmon resonance</title><p>Kinetic analyses were performed at 25 °C using a BIAcore 3000 machine (GE Healthcare Technologies). A2p1, B10p2, C10p2, E11p2, G6p2, A6p4, D4p4, D11p4, or G12p4 antibodies were immobilized on a CM5 sensor chip (GE Healthcare Technologies) with an amine-coupling kit according to the manufacturer’s instructions. HA probes were serially diluted at five different concentrations and injected at a flow rate of 30 µL/min for 3 min with a dissociation time of 7 min in HBS–EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% Surfactant P20). The chip was regenerated using 10 mM glycine (pH 2.5) as an HA probe.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Software, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Software, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con8"><p>Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were performed using protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the RIKEN Yokohama Branch (Project title: Immunological memory and vaccine development/Approval No.: 2019-001).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables.</title><p>(a) Oligonucleotides. (b) Oligonucleotides.</p></caption><media xlink:href="elife-95346-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95346-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All raw and processed sequencing data generated in this study have been submitted to the <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">NCBI Gene Expression Omnibus</ext-link> (GEO) under accession number GSE140720.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Ohara</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Immunization with two heterotypic influenza hemagglutinins by time difference effectively produces broadly binding antibodies against heterotypic influenza virus</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140720">GSE140720</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Mr. Atsuo Kobayashi, Ms. Chieko Okamura, Dr. Seok-Won Kim, Mr. Maxime Hebrard, Dr. Todd D Taylor, and the RIKEN IMS Genome Platform for their technical support, Dr. Atsushi Miyawaki for gifting the Venus gene, and Dr. Christopher Nicholas for critical reading and English editing of the manuscript. We would like to thank Editage (<ext-link ext-link-type="uri" xlink:href="https://www.editage.com">https://www.editage.com</ext-link>) for English language editing. This study was supported in part by research grants from the RIKEN Research Program ‘Single cell Project’ (OO, TW, TK, and HF) and Grants-in-Aid for Scientific Research (S) [26221306 to TK and HF]. The funding sources were not involved in the study design, data collection and interpretation, or paper submission decisions.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Daio</surname><given-names>R</given-names></name><name><surname>Tsuiji</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Ato</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Distinct germinal center selection at local sites shapes memory B cell response to viral escape</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>1709</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1084/jem.20142284</pub-id><pub-id pub-id-type="pmid">26324444</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamyar</surname><given-names>E</given-names></name><name><surname>Duroux</surname><given-names>P</given-names></name><name><surname>Giudicelli</surname><given-names>V</given-names></name><name><surname>Lefranc</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IMGT tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS</article-title><source>Methods in Molecular Biology</source><volume>882</volume><fpage>569</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-842-9_32</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balsitis</surname><given-names>SJ</given-names></name><name><surname>Williams</surname><given-names>KL</given-names></name><name><surname>Lachica</surname><given-names>R</given-names></name><name><surname>Flores</surname><given-names>D</given-names></name><name><surname>Kyle</surname><given-names>JL</given-names></name><name><surname>Mehlhop</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Beatty</surname><given-names>PR</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification</article-title><source>PLOS Pathogens</source><volume>6</volume><elocation-id>e1000790</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000790</pub-id><pub-id pub-id-type="pmid">20168989</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clackson</surname><given-names>T</given-names></name><name><surname>Hoogenboom</surname><given-names>HR</given-names></name><name><surname>Griffiths</surname><given-names>AD</given-names></name><name><surname>Winter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Making antibody fragments using phage display libraries</article-title><source>Nature</source><volume>352</volume><fpage>624</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/352624a0</pub-id><pub-id pub-id-type="pmid">1907718</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Angelo</surname><given-names>S</given-names></name><name><surname>Ferrara</surname><given-names>F</given-names></name><name><surname>Naranjo</surname><given-names>L</given-names></name><name><surname>Erasmus</surname><given-names>MF</given-names></name><name><surname>Hraber</surname><given-names>P</given-names></name><name><surname>Bradbury</surname><given-names>ARM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Many routes to an antibody heavy-chain cdr3: necessary, yet insufficient, for specific binding</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>395</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00395</pub-id><pub-id pub-id-type="pmid">29568296</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Kashyap</surname><given-names>AK</given-names></name><name><surname>Steel</surname><given-names>J</given-names></name><name><surname>Rubrum</surname><given-names>A</given-names></name><name><surname>Bhabha</surname><given-names>G</given-names></name><name><surname>Khayat</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Dillon</surname><given-names>MA</given-names></name><name><surname>O’Neil</surname><given-names>RE</given-names></name><name><surname>Faynboym</surname><given-names>AM</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Horowitz</surname><given-names>L</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Bhatt</surname><given-names>RR</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cross-neutralization of influenza a viruses mediated by a single antibody loop</article-title><source>Nature</source><volume>489</volume><fpage>526</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nature11414</pub-id><pub-id pub-id-type="pmid">22982990</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>XT</given-names></name><name><surname>Sehlin</surname><given-names>D</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Syvänen</surname><given-names>S</given-names></name><name><surname>Hultqvist</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells</article-title><source>Biological Procedures Online</source><volume>19</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1186/s12575-017-0060-7</pub-id><pub-id pub-id-type="pmid">28932173</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldhaus</surname><given-names>MJ</given-names></name><name><surname>Siegel</surname><given-names>RW</given-names></name><name><surname>Opresko</surname><given-names>LK</given-names></name><name><surname>Coleman</surname><given-names>JR</given-names></name><name><surname>Feldhaus</surname><given-names>JMW</given-names></name><name><surname>Yeung</surname><given-names>YA</given-names></name><name><surname>Cochran</surname><given-names>JR</given-names></name><name><surname>Heinzelman</surname><given-names>P</given-names></name><name><surname>Colby</surname><given-names>D</given-names></name><name><surname>Swers</surname><given-names>J</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Wiley</surname><given-names>HS</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library</article-title><source>Nature Biotechnology</source><volume>21</volume><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/nbt785</pub-id><pub-id pub-id-type="pmid">12536217</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamblin</surname><given-names>SJ</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Influenza hemagglutinin and neuraminidase membrane glycoproteins</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>28403</fpage><lpage>28409</lpage><pub-id pub-id-type="doi">10.1074/jbc.R110.129809</pub-id><pub-id pub-id-type="pmid">20538598</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>BR</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name><name><surname>Hayhurst</surname><given-names>A</given-names></name><name><surname>Jeong</surname><given-names>KJ</given-names></name><name><surname>Iverson</surname><given-names>BL</given-names></name><name><surname>Rogers</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from <italic>Escherichia coli</italic>-expressed libraries</article-title><source>PNAS</source><volume>101</volume><fpage>9193</fpage><lpage>9198</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400187101</pub-id><pub-id pub-id-type="pmid">15197275</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Impagliazzo</surname><given-names>A</given-names></name><name><surname>Milder</surname><given-names>F</given-names></name><name><surname>Kuipers</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>MV</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hoffman</surname><given-names>RMB</given-names></name><name><surname>van Meersbergen</surname><given-names>R</given-names></name><name><surname>Huizingh</surname><given-names>J</given-names></name><name><surname>Wanningen</surname><given-names>P</given-names></name><name><surname>Verspuij</surname><given-names>J</given-names></name><name><surname>de Man</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Apetri</surname><given-names>A</given-names></name><name><surname>Kükrer</surname><given-names>B</given-names></name><name><surname>Sneekes-Vriese</surname><given-names>E</given-names></name><name><surname>Tomkiewicz</surname><given-names>D</given-names></name><name><surname>Laursen</surname><given-names>NS</given-names></name><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Zakrzewska</surname><given-names>A</given-names></name><name><surname>Dekking</surname><given-names>L</given-names></name><name><surname>Tolboom</surname><given-names>J</given-names></name><name><surname>Tettero</surname><given-names>L</given-names></name><name><surname>van Meerten</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Koudstaal</surname><given-names>W</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Meijberg</surname><given-names>W</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Radošević</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A stable trimeric influenza hemagglutinin stem as A broadly protective immunogen</article-title><source>Science</source><volume>349</volume><fpage>1301</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1126/science.aac7263</pub-id><pub-id pub-id-type="pmid">26303961</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplon</surname><given-names>H</given-names></name><name><surname>Crescioli</surname><given-names>S</given-names></name><name><surname>Chenoweth</surname><given-names>A</given-names></name><name><surname>Visweswaraiah</surname><given-names>J</given-names></name><name><surname>Reichert</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Antibodies to watch in 2023</article-title><source>mAbs</source><volume>15</volume><elocation-id>2153410</elocation-id><pub-id pub-id-type="doi">10.1080/19420862.2022.2153410</pub-id><pub-id pub-id-type="pmid">36472472</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchmaier</surname><given-names>S</given-names></name><name><surname>Lust</surname><given-names>K</given-names></name><name><surname>Wittbrodt</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Golden GATEway cloning--a combinatorial approach to generate fusion and recombination constructs</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e76117</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0076117</pub-id><pub-id pub-id-type="pmid">24116091</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köhler</surname><given-names>G</given-names></name><name><surname>Milstein</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Continuous cultures of fused cells secreting antibody of predefined specificity</article-title><source>Nature</source><volume>256</volume><fpage>495</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1038/256495a0</pub-id><pub-id pub-id-type="pmid">1172191</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubota-Koketsu</surname><given-names>R</given-names></name><name><surname>Mizuta</surname><given-names>H</given-names></name><name><surname>Oshita</surname><given-names>M</given-names></name><name><surname>Ideno</surname><given-names>S</given-names></name><name><surname>Yunoki</surname><given-names>M</given-names></name><name><surname>Kuhara</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors</article-title><source>Biochemical and Biophysical Research Communications</source><volume>387</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.06.151</pub-id><pub-id pub-id-type="pmid">19580789</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuraoka</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Nojima</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex antigens drive permissive clonal selection in germinal centers</article-title><source>Immunity</source><volume>44</volume><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.010</pub-id><pub-id pub-id-type="pmid">26948373</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwakkenbos</surname><given-names>MJ</given-names></name><name><surname>Diehl</surname><given-names>SA</given-names></name><name><surname>Yasuda</surname><given-names>E</given-names></name><name><surname>Bakker</surname><given-names>AQ</given-names></name><name><surname>van Geelen</surname><given-names>CMM</given-names></name><name><surname>Lukens</surname><given-names>MV</given-names></name><name><surname>van Bleek</surname><given-names>GM</given-names></name><name><surname>Widjojoatmodjo</surname><given-names>MN</given-names></name><name><surname>Bogers</surname><given-names>WMJM</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Radbruch</surname><given-names>A</given-names></name><name><surname>Scheeren</surname><given-names>FA</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>Beaumont</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming</article-title><source>Nature Medicine</source><volume>16</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/nm.2071</pub-id><pub-id pub-id-type="pmid">20023635</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>NS</given-names></name><name><surname>Musayev</surname><given-names>M</given-names></name><name><surname>Johnston</surname><given-names>TS</given-names></name><name><surname>Wagner</surname><given-names>DA</given-names></name><name><surname>Henry</surname><given-names>AR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Birungi</surname><given-names>K</given-names></name><name><surname>Black</surname><given-names>WP</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Moon</surname><given-names>D</given-names></name><name><surname>Lorang</surname><given-names>CG</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Boswell</surname><given-names>KL</given-names></name><name><surname>Roberts-Torres</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>RL</given-names></name><name><surname>Peyton</surname><given-names>L</given-names></name><name><surname>Narpala</surname><given-names>SR</given-names></name><name><surname>O’Connell</surname><given-names>S</given-names></name><name><surname>Serebryannyy</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Schrager</surname><given-names>A</given-names></name><name><surname>Talana</surname><given-names>CA</given-names></name><name><surname>Shimberg</surname><given-names>G</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Khashab</surname><given-names>R</given-names></name><name><surname>Biber</surname><given-names>A</given-names></name><name><surname>Zilberman</surname><given-names>T</given-names></name><name><surname>Rhein</surname><given-names>J</given-names></name><name><surname>Vetter</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Novik</surname><given-names>L</given-names></name><name><surname>Widge</surname><given-names>A</given-names></name><name><surname>Gordon</surname><given-names>I</given-names></name><name><surname>Guech</surname><given-names>M</given-names></name><name><surname>Teng</surname><given-names>I-T</given-names></name><name><surname>Phung</surname><given-names>E</given-names></name><name><surname>Ruckwardt</surname><given-names>TJ</given-names></name><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>Misasi</surname><given-names>J</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Gaudinski</surname><given-names>M</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><name><surname>Schacker</surname><given-names>TW</given-names></name><name><surname>Levy</surname><given-names>I</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Sullivan</surname><given-names>NJ</given-names></name><name><surname>Schramm</surname><given-names>CA</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>7733</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-35456-2</pub-id><pub-id pub-id-type="pmid">36517467</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazor</surname><given-names>Y</given-names></name><name><surname>Van Blarcom</surname><given-names>T</given-names></name><name><surname>Mabry</surname><given-names>R</given-names></name><name><surname>Iverson</surname><given-names>BL</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Isolation of engineered, full-length antibodies from libraries expressed in <italic>Escherichia coli</italic></article-title><source>Nature Biotechnology</source><volume>25</volume><fpage>563</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/nbt1296</pub-id><pub-id pub-id-type="pmid">17435747</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>P-J</given-names></name><name><surname>Andersen</surname><given-names>PS</given-names></name><name><surname>Haahr Hansen</surname><given-names>M</given-names></name><name><surname>Steinaa</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>A</given-names></name><name><surname>Lantto</surname><given-names>J</given-names></name><name><surname>Oleksiewicz</surname><given-names>MB</given-names></name><name><surname>Tengbjerg</surname><given-names>K</given-names></name><name><surname>Poulsen</surname><given-names>TR</given-names></name><name><surname>Coljee</surname><given-names>VW</given-names></name><name><surname>Bregenholt</surname><given-names>S</given-names></name><name><surname>Haurum</surname><given-names>JS</given-names></name><name><surname>Nielsen</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing</article-title><source>Journal of Molecular Biology</source><volume>358</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.02.040</pub-id><pub-id pub-id-type="pmid">16563430</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Ibata</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Mikoshiba</surname><given-names>K</given-names></name><name><surname>Miyawaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications</article-title><source>Nature Biotechnology</source><volume>20</volume><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nbt0102-87</pub-id><pub-id pub-id-type="pmid">11753368</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Isegawa</surname><given-names>Y</given-names></name><name><surname>Sasao</surname><given-names>F</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains</article-title><source>Journal of Virology</source><volume>67</volume><fpage>2552</fpage><lpage>2558</lpage><pub-id pub-id-type="doi">10.1128/JVI.67.5.2552-2558.1993</pub-id><pub-id pub-id-type="pmid">7682624</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petropoulos</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phage display</article-title><source>Methods in Molecular Biology</source><volume>901</volume><fpage>33</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-931-0_3</pub-id><pub-id pub-id-type="pmid">22723093</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaffitzel</surname><given-names>C</given-names></name><name><surname>Hanes</surname><given-names>J</given-names></name><name><surname>Jermutus</surname><given-names>L</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Ribosome display: an in vitro method for selection and evolution of antibodies from libraries</article-title><source>Journal of Immunological Methods</source><volume>231</volume><fpage>119</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/s0022-1759(99)00149-0</pub-id><pub-id pub-id-type="pmid">10648932</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setliff</surname><given-names>I</given-names></name><name><surname>Shiakolas</surname><given-names>AR</given-names></name><name><surname>Pilewski</surname><given-names>KA</given-names></name><name><surname>Murji</surname><given-names>AA</given-names></name><name><surname>Mapengo</surname><given-names>RE</given-names></name><name><surname>Janowska</surname><given-names>K</given-names></name><name><surname>Richardson</surname><given-names>S</given-names></name><name><surname>Oosthuysen</surname><given-names>C</given-names></name><name><surname>Raju</surname><given-names>N</given-names></name><name><surname>Ronsard</surname><given-names>L</given-names></name><name><surname>Kanekiyo</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>JS</given-names></name><name><surname>Kramer</surname><given-names>KJ</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>McDonnell</surname><given-names>WJ</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>High-Throughput mapping of b cell receptor sequences to antigen specificity</article-title><source>Cell</source><volume>179</volume><fpage>1636</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.11.003</pub-id><pub-id pub-id-type="pmid">31787378</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soni</surname><given-names>P</given-names></name><name><surname>Yasuhara</surname><given-names>A</given-names></name><name><surname>Takenaga</surname><given-names>T</given-names></name><name><surname>Iwatsuki-Horimoto</surname><given-names>K</given-names></name><name><surname>Uraki</surname><given-names>R</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name><name><surname>Yamayoshi</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus</article-title><source>The Journal of Veterinary Medical Science</source><volume>80</volume><fpage>1020</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1292/jvms.18-0146</pub-id><pub-id pub-id-type="pmid">29669959</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traggiai</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Kolesnikova</surname><given-names>L</given-names></name><name><surname>Uematsu</surname><given-names>Y</given-names></name><name><surname>Gismondo</surname><given-names>MR</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</article-title><source>Nature Medicine</source><volume>10</volume><fpage>871</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nm1080</pub-id><pub-id pub-id-type="pmid">15247913</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchaninova</surname><given-names>MA</given-names></name><name><surname>Davydov</surname><given-names>A</given-names></name><name><surname>Britanova</surname><given-names>OV</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Bikos</surname><given-names>V</given-names></name><name><surname>Egorov</surname><given-names>ES</given-names></name><name><surname>Kirgizova</surname><given-names>VI</given-names></name><name><surname>Merzlyak</surname><given-names>EM</given-names></name><name><surname>Staroverov</surname><given-names>DB</given-names></name><name><surname>Bolotin</surname><given-names>DA</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Izraelson</surname><given-names>M</given-names></name><name><surname>Logacheva</surname><given-names>MD</given-names></name><name><surname>Kladova</surname><given-names>O</given-names></name><name><surname>Plevova</surname><given-names>K</given-names></name><name><surname>Pospisilova</surname><given-names>S</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>High-quality full-length immunoglobulin profiling with unique molecular barcoding</article-title><source>Nature Protocols</source><volume>11</volume><fpage>1599</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.093</pub-id><pub-id pub-id-type="pmid">27490633</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Langley</surname><given-names>WA</given-names></name><name><surname>Kokko</surname><given-names>K</given-names></name><name><surname>Larsen</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>N-Y</given-names></name><name><surname>Mays</surname><given-names>I</given-names></name><name><surname>Garman</surname><given-names>L</given-names></name><name><surname>Helms</surname><given-names>C</given-names></name><name><surname>James</surname><given-names>J</given-names></name><name><surname>Air</surname><given-names>GM</given-names></name><name><surname>Capra</surname><given-names>JD</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rapid cloning of high-affinity human monoclonal antibodies against influenza virus</article-title><source>Nature</source><volume>453</volume><fpage>667</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/nature06890</pub-id><pub-id pub-id-type="pmid">18449194</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>JL</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities</article-title><source>Immunity</source><volume>13</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)00006-6</pub-id><pub-id pub-id-type="pmid">10933393</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95346.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>Pramod K</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>UConn Health</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>The <bold>useful</bold> studies described here are broadly applicable to all antibody discovery subfields, even though they are not a significant improvement over published methods. The findings are <bold>incomplete</bold> with respect to the methodology, since details that are crucial in order to repeat the experiments are lacking (such as a timestamp). They also do not take into account multiple recent papers that have tested similar strategies. These studies will be of interest to a specialized audience working on generating antibodies to infectious agents.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95346.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This paper by Watanabe et al described an expression system that can express the paired heavy and light chains of IgG antibodies from single cell B cells. In addition, they used FACS sorting for specific antigen to screen/select the specific populations for more targeted cloning of mAb genes. By staining with multiple antigens, they were able to zoom in to cross-reactive antibodies.</p><p>Strengths:</p><p>A highly efficient process which combines selection/screening with dua expression of both antibody chains. It is particularly suitable for isolation of cross-reactive antibodies against conserved epitopes of different antigens, such as surface proteins of related viruses.</p><p>Weaknesses:</p><p>(1) The overall writing is very difficult to follow and the authors need to work on significant re-writing</p><p>(2) The paper in its current form really lacks detail and it is not possible for readers to repeat or follow their methods. For example: (a) It is not clear whether the authors checked the serum to see if the mice were producing antibodies before they sacrificed them to harvest spleen/blood i.e. using ELISA? (b) How long after administration of the second dose were the mice sacrificed? (c) What cell types are taken for single B cell sorting? Splenocytes or PBMC? These are just some of the questions which need to be addressed.</p><p>(3) According to the authors, 77 clones were sorted from the PR8+ and H2+ double positive quadrant. It is surprising that after transfection and re-analysing of bulk antibody presenting EXPI cells on FACS from, only 13 clones (or 8 clones? - unclear) seemed to be truly cross reactive. If that is the case, the approach is not as efficient as the authors claimed.</p><p>The authors have adequately addressed the issues raised</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95346.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Watanabe, Takashi et al. investigated the use of the Golden Gate dual-expression vector system to enhance the modern standard for rapid screening of recombinant monoclonal antibodies. The presented data builds upon modern techniques that currently use multiple expression vectors to express heavy and light chain pairs. In a single vector, they express the linked heavy and light chain variable genes with a membrane-bound Ig which allows for rapid and more affordable cell-based screening. The final validation of H1 and H2 strain influenza screening resulted in 81 &quot;H1+&quot;, 48 &quot;H2+&quot;, and 9 &quot;cross&quot; reactive clones. The kinetics of some of the soluble antibodies were tested via SPR and validated with a competitive inhibition with classical well-characterized neutralizing clones.</p><p>Strengths:</p><p>In this study, Watanabe, Takashi et al. further develop and refine the methodologies for the discovery of monoclonal antibodies. They elegantly merge newer technologies to speed up turnaround time and reduce the cost of antibody discovery. Their data supports the feasibility of their technique.</p><p>This study will have an impact on pandemic preparedness and antibody-based therapies.</p><p>Weaknesses:</p><p>Limitations of this new technique are as follows: there is a significant loss of cells during FACs, transfection and cloning efficiency are critical to success, and well-based systems limit the number of possible clones (as the author discussed in the conclusions).</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95346.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Takashi</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hata</surname><given-names>Hikaru</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Mochizuki</surname><given-names>Yoshiki</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Fumie</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hasegawa</surname><given-names>Tomoko</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Naveen</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role specific-use="author">Author</role><aff><institution>RIKEN Center for Integrative Medical Sciences</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ohara</surname><given-names>Osamu</given-names></name><role specific-use="author">Author</role><aff><institution>Kazusa DNA Research Institute</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Fukuyama</surname><given-names>Hidehiro</given-names></name><role specific-use="author">Author</role><aff><institution>Kansai Medical University</institution><addr-line><named-content content-type="city">Hirakata</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>(1) The overall writing is very difficult to follow and the authors need to work on significant re-writing.</p></disp-quote><p>Thank you for your comment. We have rewritten the text and asked an immunology expert, who is also a native English speaking editor, to review it.</p><disp-quote content-type="editor-comment"><p>(2) The paper in its current form really lacks detail and it is NOT possible for readers to repeat or follow their methods. For example: (a) It is not clear whether the authors checked the serum to see if the mice were producing antibodies before they sacrificed them to harvest spleen/blood i.e. using ELISA? (b) How long after administration of the second dose were the mice sacrificed? (c) What cell types are taken for single B cell sorting? Splenocytes or PBMC?</p></disp-quote><p>Thank you for your comment. We have revised the methodology section thoroughly to ensure that the readers can follow and replicate the method. Our responses to the specific examples raised are as follows:</p><p>a) We did not examine the serum titer after immunization. An increased serum titer, as determined by ELISA, does not always reflect the number of cross-reactive B cells because we expected the serum titer to consist of polyclonal antibodies, which are a mixture of PR8-reactive, H2-reactive, and cross-reactive clones. We thus anticipated that we would not obtain enough cross-reactive B cells after a series of immunizations. After comparing various immunization methods, including different adjuvants and immunization sites, using the readout of the number of cross-reactive B cells, we decided to adopt the immunization protocol presented in this paper.</p><p>b) We sacrificed the mice two weeks after the second immunization (see Supplementary Figure 5).</p><p>c) For this experiment, we used CD43 MACS B cells from the spleen purified with negatively charged beads (see Supplementary Figure 6).</p><disp-quote content-type="editor-comment"><p>(3) According to the authors, 77 clones were sorted from the PR8+ and H2+ double positive quadrant. It is surprising that after transfection and re-analyzing of bulk antibody presenting EXPI cells on FACS, only 13 clones (or 8 clones? - unclear) seemed to be truly cross-reactive. If that is the case, the approach is not as efficient as the authors claimed.</p></disp-quote><p>Thank you for your comment. To isolate high affinity antibodies, we gated the high fluorescent intensity population of cross-reactive B cells during Ig-expressing 293 cell sorting, as shown in Fig 2B, while we collected a wide intensity population of cross-reactive cells during splenocyte sorting. The narrow gating reduced the number of clones. We, however, cannot quantify how many clones we lost in the process, but we achieved a cloning efficiency exceeding 75%. To avoid any confusion, we have clarified this point by attaching additional supplementary figures (Supplementary Figures 5 and 6).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>(4) A His tagged antigen was used for immunization and H1-his was used in all assays. Either the removal of His specific clones needs to be done before selection, or a different tag needs to be used in the subsequent assays.</p></disp-quote><p>Thank you for your comment. As pointed out, the possibility of antibody generation in regions other than HA cannot be ruled out since the immunized antigen and the detection antigen were the same. However, as shown in Table 1, the cross-reactive antibodies obtained in this study exhibited characteristic binding abilities to each of the six types of HA. If these were antibodies recognizing His, they would bind to all six types of HA. This indicates that these cross-reactive antibodies were not His-specific clones.</p><p>We have incorporated information on this potential caveat into the discussion (page 12, lines 4-9).</p><disp-quote content-type="editor-comment"><p>(5) This assay doesn't directly test the neutralization of influenza but rather equates viral clearance to competitive inhibition. The results would be strengthened with the demonstration of a functional antibody in vivo with viral clearance.</p></disp-quote><p>Thank you for your constructive comment. While we agree that demonstration of a functional antibody in vivo with viral clearance would strengthen our results, this is clearly out of the scope of our current study and will be subject of future research.</p><disp-quote content-type="editor-comment"><p>(6) Limitations of this new technique are as follows: there is a significant loss of cells during FACs, transfection and cloning efficiency are critical to success, and well-based systems limit the number of possible clones (as the author discussed in the conclusions). Early enrichment of the B cells could improve efficiency, such as selection for memory B cells.</p></disp-quote><p>Thank you for your comment. Our cloning efficiency for sorted B cells exceeded 75%. However, we selected high binders of cross-reactive B cells during Ig-expressing 293 functional screening on purpose, as shown in Figure 2B, while we collected all cross-reactive B cells during B cell sorting (see attached Supplementary Figure 5). This functional selection step reduced the number of clones. We clarified this point by attaching additional supplementary figures (Supplementary Figures 5 and 6).</p><p>Our sorted cross-reactive B cells are most likely CD38+ memory B cells, as shown in Supplementary Figure 6.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>a) It is advised for the authors to provide a flow chart with time stamps to prove the many statements made in the paper. For example, it is stated that &quot;we demonstrated efficient isolation of influenza cross-reactive antibodies with high affinity from mouse germinal B cells over 4 days&quot;. It is not clear how this was calculated.</p></disp-quote><p>Thank you for your comment. We have prepared a time-stamped flow chart (Supplementary Figure 5).</p><disp-quote content-type="editor-comment"><p>b) The papers cited by the authors are relatively old if not outdated. There are many papers published focusing on efficient isolation of mAbs for SARS-CoV-2 research. For example, the paper by Lima et al (Nat Comm 2022, 13:7733) used a very similar strategy for rapid isolation of cross-reactive mAbs by FACS sorting followed by cloning of paired heavy and light chains from single B cells. The authors need to incorporate citations from the latest publications in this field.</p></disp-quote><p>Thank you for your comment. The paper by Lima et al. (Nat Comm 2022, 13:7733) has been cited in the Discussion as ref 28.</p><disp-quote content-type="editor-comment"><p>c) Figure 2 needs much more detail for readers to follow.</p></disp-quote><p>Thank you for your comment. We have revised the legend of Figure 2 accordingly and added additional supplementary figures (Supplementary Figures 5 and 6) to increase clarity.</p></body></sub-article></article>